Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients
PROTEOMICS · 2025
DOI: 10.1002/pmic.202400354 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS, 2025. Verfasst von Emily M Martin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nordic Bioscience A/S, Herlev, Denmark. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Collagen Type III, Kidney. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon Europe Marie Skłodowska-Curie Actions Doctoral Networks-Industrial Doctorates Programme.
Abstract (Originalsprache)
A common hallmark of chronic kidney disease (CKD) is kidney fibrosis, which manifests as an increased deposition and turnover of collagens in the kidneys. Current clinical methods of monitoring disease progression in CKD patients do not truly reflect alterations at the tissue level without the use of invasive biopsies. Naturally occurring urinary peptides associated with kidney function and fibrosis have been previously identified using CE‐MS as a non‐invasive alternative. Moreover, a specific peptide from collagen type III, a highly abundant interstitial collagen, is the target for the C3M enzyme‐linked immunosorbent assay (ELISA)‐based assay and has been recorded in the CKD273 urinary biomarker panel measured by CE‐MS. We aimed to investigate the intensities of the peptides incorporating the C3M sequence captured by CE‐MS in urine of patients with CKD and analyze their association with estimated glomerular filtration rate (eGFR) and kidney interstitial fibrosis and tubular atrophy (IFTA). The investigated collagen type III peptides were reduced in abundance in urine of patients with CKD compared to healthy controls and the peptide intensities were independently correlated to eGFR and inversely correlated with IFTA score. Collectively, this analysis supports that peptides containing the C3M sequence are significantly associated with kidney function decline and tissue fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nordic Bioscience A/S, Herlev, Denmark.
- University of Copenhagen, Copenhagen, Denmark.
- Mosaiques Diagnostics GmbH, Hannover, Germany.
- Department of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany.
- Department of Nephrology, Medizincampus Oberfranken, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- Kuratorium for Dialysis and Transplantation (KfH), Bayreuth, Bayreuth, Germany.
ORCID-Profile: Emily M Martin, Justyna Siwy, Agnieszka Latosinska
Förderung
- European Union's Horizon Europe Marie Skłodowska-Curie Actions Doctoral Networks-Industrial Doctorates Programme
Zitieren
APA
Martin, E. M., Genovese, F., Mischak, H., Siwy, J., Rupprecht, H., Catanese, L., & Latosinska, A. (2025). Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients. PROTEOMICS. https://doi.org/10.1002/pmic.202400354
Vancouver
Martin EM, Genovese F, Mischak H, Siwy J, Rupprecht H, Catanese L, et al. Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients. PROTEOMICS. 2025. doi:10.1002/pmic.202400354
BibTeX
@article{Martin2025,
author = {Martin, Emily M and Genovese, Federica and Mischak, Harald and Siwy, Justyna and Rupprecht, Harald and Catanese, Lorenzo and Latosinska, Agnieszka},
title = {Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients},
journal = {PROTEOMICS},
year = {2025},
doi = {10.1002/pmic.202400354}
}
EUVIMED